Entremed Drug Gets Orphan Status in Ovarian Cancer (Reuters


Reuters - EntreMed Inc. said on Thursday that
U.S. regulators will grant its experimental treatment for
ovarian cancer a seven-year period of market exclusivity if it
is approved.

Read more...